Healthy Adults
Conditions
Interventions
None listed
Sponsors
Japan Clinical Trial Association
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants (P) Participants were defined as healthy adult men and women who subjectively experience transient psychological stress and fatigue. Individuals with diagnosed medical conditions, minors, pregnant or lactating women were excluded. Those experiencing prolonged psychological stress or fatigue were also excluded due to the potential presence of underlying health conditions. However, individuals who performed stress-inducing tasks during the study period and subsequently reported transient psychological stress or fatigue were included. Intervention (I) Intervention was defined as oral intake of foods containing gamma-aminobutyric acid (GABA). As the focus was on transient effects, intake was primarily single-dose. Studies with intake periods of several days to one week were considered if the content clearly targeted transient psychological stress and fatigue. Based on previous research, studies administering 25mg to 100mg of GABA were included, with 28mg commonly regarded as an effective dose. Studies were grouped by dosage: <=25mg, <=50mg, and <=100mg. Studies with unclear GABA content were excluded. Comparison (C) Comparison was defined as oral intake of foods not containing GABA. Studies containing ingredients known to affect outcomes were generally excluded. However, studies with no intake or with trace amounts of such ingredients deemed unlikely to influence outcomes were included. No further subgrouping was performed; all studies meeting these criteria were treated as a single comparison group. Outcome (O) The primary outcome was defined as transient alleviation of psychological stress and fatigue. Both objective and subjective indicators were evaluated, including: stress biomarkers autonomic nervous system activity electroencephalographic (EEG) measures (alpha and beta waves) subjective assessments (VAS, POMS)
Exclusion criteria
Exclusion criteria: Exclude trials that do not meet the selection criteria, such as those including individuals with diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stress biomarkers, autonomic nervous system activity, electroencephalographic (EEG) measures (alpha and beta waves), and subjective assessments (Visual Analog Scale [VAS], Profile of Mood States [POMS]) | — |
Countries
Japan
Contacts
Public ContactTakeshi Kaneko
Japan Clinical Trial Association N/A
Outcome results
None listed